Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 327 followers
Latest posts
Last updated about 2 hours ago
6 people charged in $41M insider trading scheme tied to 2 biotechs
about 2 hours ago
Six people, including a former employee of investment bank Citigroup’s San Francisco...
Abbott’s Volt pulsed field ablation system scores FDA approval
about 6 hours ago
With the U.S. green light, Abbott’s newcomer will compete with hardware with...
BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement
about 6 hours ago
Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped...
Editor's corner: Fierce Medtech's top 10 stories of 2025 show how tech can treat
about 7 hours ago
One main thread in our most-read stories of 2025 is that new...
Gilead pays $35M to license pair of HSV assets from Assembly Bio pact
about 7 hours ago
Two years after Gilead secured the first option on Assembly Biosciences’ entire...
Hologic breast cancer study bolsters use of mammogram AI
about 7 hours ago
Hologic put forward another study that bolsters the use of its mammography...
Boehringer spells out a $448M future for Rectify's ABC kidney disease program
about 8 hours ago
Boehringer Ingelheim has opened another front in its attack on chronic kidney...
Big Pharma-backed Aktis plans IPO to fund radiopharma trials
about 8 hours ago
Big Pharma-backed Aktis Oncology has announced plans to go public in the...
Novo Holdings-backed Windward buys rights to Qyuns' clinical-stage immunology bispecific in $700M deal
about 10 hours ago
Having kicked off the year with a $200 million series A, Windward...
Ipsen continues ADC push with $1B deal for Simcere's preclinical LRRC15-targeting asset
about 10 hours ago
Ipsen may be a recent entrant into the antibody-drug conjugate space, but...
AstraZeneca fronts $100M for Jacobio’s clinical-stage pan-KRAS inhibitor
about 12 hours ago
AstraZeneca has fronted $100 million to head deeper into the KRAS space...
AstraZeneca flunks phase 3 lung cancer test in further setback to synthetic lethal mechanism
about 13 hours ago
A phase 3 study of AstraZeneca’s ceralasertib has missed its primary endpoint...